You are here

BCRF Grantee Since

2003

Donor Recognition

The Estée Lauder Award

Vered Stearns, MD

Professor of Oncology
Co-Director, Breast Cancer Program
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins School of Medicine
Baltimore, Maryland
Member, BCRF Scientific Advisory Board

Current Research

Excess body weight is a major risk factor for many cancers, including breast cancer. In addition, once diagnosed with breast cancer, women who are overweight or obese suffer worse outcomes. The overall goal of Dr. Stearns’s BCRF research is to determine the effectiveness of a remote (telephone-based) dietary counseling program in overweight or obese women with early stage breast cancer. The trial will evaluate the effects of the intervention on weight loss to predict which breast cancer patients are most likely to benefit, and the data will be used to implement a standard clinical program for overweight and obese breast cancer patients being treated at Johns Hopkins. The study will also provide a platform for larger prospective studies to investigate the effects of weight loss on breast cancer outcomes, towards a goal of personalized approaches for the prevention of breast cancer.

Bio

Dr. Stearns joined the faculty at the Breast Cancer Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in 2002. She was appointed as co-Director of the Breast Cancer Program in 2010, and to full Professor in 2013.

Dr. Stearns’s long-term research goal is to improve current therapies by individualizing strategies for the treatment and prevention of breast cancer. Her main research includes utilization of biomarkers to predict response to standard regimens used to treat and prevent breast cancer and to introduce new treatments.  Dr. Stearns and colleagues from the Consortium On Breast Cancer Pharmacogenomics (COBRA) Group were the first to evaluate the role of genetic variants in candidate genes such as CYP2D6 in tamoxifen metabolism, safety, and efficacy. The work has been extended to evaluate the role of genetic variants in aromatase inhibitor associated outcomes.